Skip to main content

Table 2 NCCN recommended single agents and combination regimens

From: Evaluation of the accuracy of algorithms to identify soft tissue sarcoma (STS) in administrative claims

Single agents
Doxorubicin
Ifosfamide
Epirubicin
Gemcitabine
Dacarbazine
Liposomal doxorubicin
Temozolomide
Vinorelbine
Eribulin
Trabectedin
Pazopanib
Regorafenib
Larotrectinib
Combination regimens
AD: doxorubicin, dacarbazine
AIM: doxorubicin, ifosfamide, mesna
MAID: mesna, doxorubicin, ifosfamide, dacarbazine
Ifosfamide, epirubicin, mesna
Gemcitabine and docetaxel
Gemcitabine and vinorelbine
Gemcitabine and dacarbazine
Doxorubicin and olaratumab (October 2016- July 2018 only)